Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals has received notification from the United States Patent and Trademark Office (USPTO) that two additional patents covering FIRDAPSE® (amifampridine) Tablets 10 mg will be granted within the next two months. These patents are associated with the unique bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.
November 02, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The granting of two new patents for FIRDAPSE by the USPTO strengthens Catalyst Pharmaceuticals' intellectual property portfolio and safeguards the commercial viability of FIRDAPSE, which is the only approved treatment for Lambert-Eaton myasthenic syndrome in the U.S.
The granting of two new patents for FIRDAPSE strengthens Catalyst Pharmaceuticals' intellectual property portfolio. This is likely to have a positive impact on the company's stock as it safeguards the commercial viability of FIRDAPSE, which is the only approved treatment for Lambert-Eaton myasthenic syndrome in the U.S. The patents also extend the exclusivity protection of FIRDAPSE in the U.S. until 2037, providing a long-term competitive advantage for Catalyst Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100